Subtype
Human Papillomavirus-Related Pharyngeal Squamous Cell Carcinoma
CI-CAN-00007825Explore in graph →
30 active trials
- NCIt
- C213332
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007825Explore in graph →
Clinical trials
54 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(VERSATILE-003) | terminated | Phase 3 | 12 | PDS Biotechnology Corp.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | terminated | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 |
| clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 2, 2026source: clinicaltrials